Access cutting-edge mantle cell lymphoma treatment through this clinical trial at a research site in Greenwich. Study-provided care at no cost to qualified participants.
Access mantle cell lymphoma specialists in Greenwich at no cost
This study follows strict safety protocols and ethical guidelines
All study-related mantle cell lymphoma treatment provided free
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used
Sponsor: Alliance for Clinical Trials in Oncology
Check if you qualify for this mantle cell lymphoma clinical trial in Greenwich, CT
If you're searching for mantle cell lymphoma treatment options in Greenwich, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Greenwich research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mantle cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.